Copyright
©The Author(s) 2024.
World J Radiol. Jan 28, 2024; 16(1): 9-19
Published online Jan 28, 2024. doi: 10.4329/wjr.v16.i1.9
Published online Jan 28, 2024. doi: 10.4329/wjr.v16.i1.9
Table 1 Demographic and clinical information of all enrolled patients receiving docetaxel, oxaliplatin and S-1
| Variable | Training cohort (n = 94) | Validation cohort (n = 34) | |
| Age, yr | 66.0 ± 7.0 | 65 ± 6.1 | |
| Gender | |||
| Male | 77 | 20 | |
| Female | 17 | 14 | |
| cT stage | |||
| cT3 | 62 | 16 | |
| cT4 | 32 | 18 | |
| cN stage | |||
| cN0 | 8 | 3 | |
| cN1 | 36 | 13 | |
| cN2 | 40 | 14 | |
| cN3 | 10 | 4 | |
| Siewert type | |||
| II | 39 | 18 | |
| III | 55 | 16 | |
| GTV (cm3) | 50.8 ± 32.0 | 51.1 ± 36.0 | |
- Citation: Zhou CQ, Gao D, Gui Y, Li NP, Guo WW, Zhou HY, Li R, Chen J, Zhang XM, Chen TW. Computed tomography-based nomogram of Siewert type II/III adenocarcinoma of esophagogastric junction to predict response to docetaxel, oxaliplatin and S-1. World J Radiol 2024; 16(1): 9-19
- URL: https://www.wjgnet.com/1949-8470/full/v16/i1/9.htm
- DOI: https://dx.doi.org/10.4329/wjr.v16.i1.9